Proud to support Breast Cancer Awareness Month by partnering with Fox Chase Cancer Center (FCCC) to make cancer screenings more accessible for everyone. Last year we officially unveiled Fox Chase's second Mobile Screening Unit (MSU), which eliminate obstacles that make it more difficult for people to access cancer screenings, such as lack of transportation, no access to health insurance, limited English proficiency, or low health literacy. Grateful for the opportunity to host the MSU at our Exton site for our team and their families. Together, we’re removing barriers to care. Watch this video to learn more about our partnership with FCCC. #WestGives #OneWestTeam

US FDA approves Merck's injectable version of blockbuster cancer therapy Keytruda The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient version of the widely used cancer immunotherapy. https://buff.ly/yVG3oVi

US FDA approves Merck's injectable version of blockbuster cancer therapy Keytruda The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient version of the widely used cancer immunotherapy. https://buff.ly/yVG3oVi

US FDA approves Merck's injectable version of blockbuster cancer therapy Keytruda The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient version of the widely used cancer immunotherapy. https://buff.ly/yVG3oVi

US FDA approves Merck's injectable version of blockbuster cancer therapy Keytruda The U.S. Food and Drug Administration said on Friday it has approved a new formulation of Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient version of the widely used cancer immunotherapy. The move marks a significant shift in how one of the world's top-selling cancer immunotherapies can be delivered, potentially improving patient experience and clinic efficiency. Source: Reuters

🚨 Breaking Medical News! The FDA has officially approved Inlexzo (Gemcitabine Intravesical System) — a groundbreaking treatment for BCG-unresponsive, non-muscle-invasive bladder cancer 💊 Developed by Johnson & Johnson, Inlexzo is the first-ever intravesical drug-releasing system designed for extended local delivery — helping patients preserve their bladder while fighting cancer effectively. In the SunRISe-1 Phase 2b trial, 82% of patients achieved complete response, with over half maintaining it for a year — a major milestone in bladder cancer care! #FDAApproved #Inlexzo #BladderCancer #OncologyUpdate #MedicalNews #CancerTreatment #Pharmacozyme #PharmacologyInsights

This post is intended for a US audience.      Today, AstraZeneca and our partners at Daiichi Sankyo announced the US FDA granted Priority Review for our HER2-directed antibody-drug conjugate (ADC) in combination with another therapy for the treatment of 1st-line HER2-positive metastatic breast cancer (mBC), based on results from the DESTINY-Breast09 Phase III trial.     HER2-positive mBC is an aggressive disease with a poor prognosis, with most patients experiencing progression within two years of 1st-line treatment. We’re aiming to bring a new treatment option into the 1st-line setting for HER2-positive mBC, where the current standard of care has been in place for more than a decade.     Learn more about what this milestone could mean for patients: https://lnkd.in/epXPDziw #USOnly #AstraZenecaUS

📢 The EMA Cancer Medicines Forum (CMF) is organising a workshop on 14 November 2025 to enable industry support for cancer treatment optimisation. 📌 The workshop aims to foster dialogue on cancer treatment optimisation, focusing on industry support for cancer treatment optimisation both during the development phase and the post-marketing authorisation process, from innovation through clinical practice, and ways to facilitate effective stakeholder dialogue and communication. 📌 Topics to be explored will include optimisation strategies related to treatment dose and duration, reward mechanism for post-marketing studies, industry’s role in supporting optimisation post-approval, and data and tissue sharing. 👉 More information and link to the agenda: https://lnkd.in/eE74VR6t 👉 Register at this link by 30 September 2025 for in-person participation and by 31 October 2025 for online participation: https://lnkd.in/eWQqjA2v

Roche has exciting news! The phase III evERA study revealed that investigational giredestrant, combined with everolimus, significantly improves progression-free survival (PFS) in patients with ER-positive, HER2-negative breast cancer who have previously undergone treatment. This breakthrough surpassed standard endocrine therapy plus everolimus for both intention-to-treat and ESR1-mutated populations. For more details: https://lnkd.in/d8z64Zhf

🧬 The KRAS inhibitor market has expanded at a rapid pace since the first FDA approval in 2021, transforming outcomes for patients with KRAS G12C mutations and driving a wave of new development.   Beacon data reveals: 🔹 400% increase in new KRAS drugs disclosed since 2021 🔹 6 inhibitors now in Phase 3, competing for the next approval (Calderasib, Daraxonrasib, Dinaciclib, Divarasib, and more) 🔹 Clinical trial initiations surged sevenfold from 2020 to 2024 (12 → 86) 🔹 Strong deal-making activity continues as KRAS-targeted therapies gain global momentum   Our new report explores KRAS clinical trial activity, 2025 deal-making trends, and insights from KRAS abstracts at the 2025 World Conference on Lung Cancer.   👉 Download the KRAS Landscape Report here: https://ter.li/7ksn3l   #KRAS #Oncology #LungCancer #ClinicalTrials #Pharma